NCT07109154Recruiting
DeniLA: Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Guideline-Concordant Care in First-line Treatment Patterns
DeniLA: Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Guideline-Concordant Care in First-line Treatment Patterns Observational Study (Prospective and Survey); Evaluation Patterns of Choice in First Line Treatment of Metastatic NSCLC
Source: ClinicalTrials.gov · Last updated 13 May 2026
Brief summary (registry, in English)
This is a prospective, observational, multicenter study, in which clinical and demographic data will be extracted from medical records. Convenience sample, with an estimated inclusion of 200 patients treated in seven participating centers. Eligible tumors for this project will be from patients with advanced (unresectable or metastatic) non-small cell lung carcinoma, who will start first-line oncological treatment in one of the participating centers between 2025 and 2026 (between January 2025 and January 2026). Patients must be over 18 years old and data must be available in electronic medical records. Medical records will be assessed to confirm patients' eligibility. Patients with localized disease amenable to local treatment, non-epithelial histology, small cell carcinoma and neuroendocrine tumor will not be eligible. A survey will be designed targeting thoracic and generalist medical oncologists, aiming to understand the factors guiding the choice of first-line treatment regimens and to compare these insights with real-world data. The survey will be directed to Brazil, with an estimated of 200 filled files.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 16 Jul 2025
- Start date
- 25 Nov 2025
- Primary completion date
- 30 Apr 2027
- Lead sponsor
- AstraZeneca
- Diseases
- Lung cancer, Childhood cancers
- NCT number
- NCT07109154
What you commit to
- Study type: Observational
- Planned participants: 200
- From 25 Nov 2025 to the primary completion date, 30 Apr 2027
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with unresectable NSCLC who underwent treatment with the PACIFIC protocol and are being followed up.
Other illness
- Localized disease amenable to local treatment
Other
- Non-epithelial histology
- Small cell carcinoma
- Neuroendocrine tumor
Who the study is looking for
- Advanced (unresectable or metastatic) non-small cell lung carcinoma
- First-line oncological treatment in one of the participating centers between 2025 and 2026 (between January 2025 and January 2026)
- \> 18 years old
- Data available in electronic medical records.
Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Recife | Brazil | Active, not recruiting |
| - Coordinator of this site? Confirm its status | Rio de Janeiro | Brazil | Recruiting |
| - Coordinator of this site? Confirm its status | Salvador | Brazil | Recruiting |
| - Coordinator of this site? Confirm its status | São Paulo | Brazil | Active, not recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.